Gain Therapeutics, Inc.
We are a biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (“LSDs”), including rare genetic diseases and neurological disorders. We use our exclusively in-licensed proprietary platform, Site-Directed Enzyme Enhancement Therapy (“SEE-Tx”), to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treating the underlying disease. As of Feb. 19, 2021, we have filed three patent applications and one provisional patent application (these do not cover the United States) for our novel Structurally Targeted Allosteric Regulators (“STARs”). These are small molecules with the potential to treat diseases with high unmet medical need, including Morquio B, GM1 Gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s disease, Krabbe disease and Mucopolysaccharidosis type 1.
(Note: Gain Therapeutics priced its IPO on March17, 2021, at $11 – the mid-point of its $10-to-$12 range – on 3.64 million shares (3,636,364 shares to be exact) to raise $40.0 million. This IPO was priced in sync with the terms in its prospectus.)
|Address||4800 Hampden Lane, Suite 200 Bethesda, MD 20814|
|Phone Number||(301) 500-1556|
|View Prospectus:||Gain Therapeutics, Inc.|
|Revenues||$0.03 mil (last 12 months)|
|Net Income||$-3.58 mil (last 12 months)|
|Price range||$11.00 - $11.00|
|Est. $ Volume||$40.0 mil|
|Manager / Joint Managers||BTIG/ Oppenheimer & Co.|
|Expected To Trade:||3/18/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|